NRG raises Series A funds for Parkinson’s and ALS therapy development
Pharmaceutical Technology Read more
NRG announces £16m Series A for IND for Parkinson’s and ALS
PharmaPhorum Read more
Following the path to a new drug, together
Parkinson’s UK Read more
NRG Therapeutics Scores $18M to Target Mitochondrial Dysfunction in Parkinson’s, ALS
Biospace Read more
GSK vets theorize that a mitochondrial target may unlock Parkinson’s and ALS treatments in new startup
Endpoints Read more
NRG gearing up for series A to advance brain-penetrant PTP inhibitors
Bioworld Read more (behind a paywall)
NRG Therapeutics and Domainex to collaborate on discovery of small molecules to treat Parkinson’s or motor neurone disease
Cambridge Independent Read more
© NRG Therapeutics
